Published in Pharma Investments, Ventures and Law Weekly, March 5th, 2006
The company and Fusion Capital Fund II, LLC have amended the agreement in response to the Nasdaq's determination. The amendment clarifies the circumstances under which shareholder approval would be required.
The Nasdaq staff has confirmed that the agreement, as amended, now complies with Nasdaq's shareholder approval rules.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.